scholarly journals Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes

2020 ◽  
Vol 81 (2) ◽  
pp. e178-e180 ◽  
Author(s):  
Furong Liu ◽  
Xin Long ◽  
Guibao Ji ◽  
Bixiang Zhang ◽  
Wanguang Zhang ◽  
...  
Keyword(s):  
Portal Hypertension ◽  
Clinical Characteristics ◽  
Clinically Significant

An unusual presentation of epigastric pain due to thrombophlebitis of a recanalised umbilical vein – case report

2019 ◽  
Vol 98 (8) ◽  
pp. 326-327 ◽  
Keyword(s):  
Liver Cirrhosis ◽  
Abdominal Pain ◽  
Case Report ◽  
Portal Hypertension ◽  
Liver Disease ◽  
Epigastric Pain ◽  
Umbilical Vein ◽  
History Of ◽  
Clinically Significant ◽  
Inflammatory Changes

Introduction: The umbilical vein can become recanalised due to portal hypertension in patients with liver cirrhosis but the condition is rarely clinically significant. Although bleeding from this enlarged vein is a known complication, the finding of thrombophlebitis has not been previously described. Case report: We report the case of a 62-year-old male with a history of liver cirrhosis due to alcoholic liver disease presenting to hospital with epigastric pain. A CT scan of the patient’s abdomen revealed a thrombus with surrounding inflammatory changes in a recanalised umbilical vein. The patient was managed conservatively and was discharged home the following day. Conclusion: Thrombophlebitis of a recanalised umbilical vein is a rare cause of abdominal pain in patients with liver cirrhosis.

scholarly journals Noninvasive Evaluation of Portal Hypertension Using a Supervised Learning Technique

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Mindaugas Marozas ◽  
Romanas Zykus ◽  
Andrius Sakalauskas ◽  
Limas Kupčinskas ◽  
Arūnas Lukoševičius
Keyword(s):  
Portal Hypertension ◽  
Supervised Learning ◽  
Evaluation Method ◽  
Clinical Laboratory ◽  
Transient Elastography ◽  
Venous Pressure ◽  
Noninvasive Evaluation ◽  
Noninvasive Methods ◽  
Supervised Learning Algorithms ◽  
Clinically Significant

Portal hypertension (PHT) is a key event in the evolution of different chronic liver diseases and leads to the morbidity and mortality of patients. The traditional reliable PHT evaluation method is a hepatic venous pressure gradient (HVPG) measurement, which is invasive and not always available or acceptable to patients. The HVPG measurement is relatively expensive and depends on the experience of the physician. There are many potential noninvasive methods to predict PHT, of which liver transient elastography is determined to be the most accurate; however, even transient elastography lacks the accuracy to be a perfect noninvasive diagnostic method of PHT. In this research, we are focusing on noninvasive PHT assessment methods that rely on selected best-supervised learning algorithms which use a wide set of noninvasively obtained data, including demographical, clinical, laboratory, instrumental, and transient elastography measurements. In order to build the best performing classification meta-algorithm, a set of 21 classification algorithms have been tested. The problem was expanded by selecting the best performing clinical attributes using algorithm-specific filtering methods that give the lowest error rate to predict clinically significant PHT. The suggested meta-algorithm objectively outperforms other methods found in literature and can be a good substitute for invasive PHT evaluation methods.

Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study

Hepatology ◽  
2016 ◽  
Vol 64 (6) ◽  
pp. 2173-2184 ◽  
Author(s):  
Juan G. Abraldes ◽  
Christophe Bureau ◽  
Horia Stefanescu ◽  
Salvador Augustin ◽  
Michael Ney ◽  
...  
Keyword(s):  
Portal Hypertension ◽  
Compensated Cirrhosis ◽  
Clinically Significant

scholarly journals Indocyanine Green Clearance as a Marker of Decompensation and Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis

2011 ◽  
Vol 140 (5) ◽  
pp. S-958 ◽  
Author(s):  
Laura Turco ◽  
Francesco Azzaroli ◽  
Federica Buonfiglioli ◽  
Andrea Lisotti ◽  
Paolo Cecinato ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Portal Hypertension ◽  
Indocyanine Green ◽  
Indocyanine Green Clearance ◽  
Clinically Significant

Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Giulia Tosetti ◽  
Elisabetta Degasperi ◽  
Elisa Farina ◽  
Roberta D'Ambrosio ◽  
Roberta Soffredini ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Portal Hypertension ◽  
Hepatitis C ◽  
Direct Acting Antiviral ◽  
Clinically Significant ◽  
Direct Acting

scholarly journals Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study

Gut ◽  
2016 ◽  
Vol 65 (6) ◽  
pp. 1057-1058 ◽  
Author(s):  
Christian Jansen ◽  
Christopher Bogs ◽  
Wim Verlinden ◽  
Maja Thiele ◽  
Philipp Möller ◽  
...  
Keyword(s):  
Portal Hypertension ◽  
Multicentre Study ◽  
Shear Wave ◽  
Shear Wave Elastography ◽  
Prospective Multicentre Study ◽  
Clinically Significant ◽  
Rule Out

scholarly journals von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e025656
Author(s):  
Ziyuan Zou ◽  
Xinwen Yan ◽  
Cheng Li ◽  
Xiaofeng Li ◽  
Xiaofen Ma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Portal Hypertension ◽  
Correlation Coefficient ◽  
Von Willebrand Factor ◽  
Diagnostic Performance ◽  
Meta Analysis ◽  
Moderate Correlation ◽  
Clinically Significant ◽  
Von Willebrand ◽  
Willebrand Factor

ObjectiveThis meta-analysis was performed to investigate the correlation between von Willebrand factor (vWF) antigen and hepatic venous pressure gradient (HVPG) and to evaluate the diagnostic performance of vWF to detect clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH).DesignSystematic review and meta-analysis.MethodsMEDLINE, EMBASE, Web of Science and the Cochrane Library were screened up to 5 April 2018. Studies related to the diagnostic performance of vWF to detect CSPH and/or SPH with HVPG as the reference standard were included. Study quality was assessed by using the Quality Assessment of Diagnostic Accuracy Studies scale. Two authors independently used a standardised form to extract data.OutcomesThe primary outcome was the correlation coefficient between vWF and HVPG. The secondary outcome was the diagnostic performance of vWF to detect CSPH or SPH.ResultsA total of six articles involving 994 patients were included in this study. Five of the included articles were used to stratify the results for the correlation coefficient, three for the diagnostic performance of CSPH and two for SPH. The pooled correlation coefficient based on the random effects model was 0.54 (95% CI 0.35 to 0.69), thus suggesting a moderate correlation between vWF and HVPG. The pooled sensitivity, specificity and area under the curve of vWF for CSPH detection were 82% (95% CI 78 to 86), 76% (95% CI 68 to 83) and 0.87 (95% CI 0.80 to 0.94), respectively. Regarding the ability of vWF to detect SPH, the pooled sensitivity and specificity were 86% (95% CI 80 to 90) and 75% (95% CI 66 to 83), respectively. These results supported the satisfactory diagnostic performance of vWF for CSPH and SPH detection.ConclusionsvWF, as a novel biomarker, has a moderate correlation with HVPG and shows a satisfactory performance for the diagnosis of CSPH and SPH in patients with cirrhosis.

Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review

2020 ◽  
Vol 40 (03) ◽  
pp. 240-255 ◽  
Author(s):  
Mattias Mandorfer ◽  
Virginia Hernández-Gea ◽  
Juan Carlos García-Pagán ◽  
Thomas Reiberger
Keyword(s):  
Portal Hypertension ◽  
Beta Blockers ◽  
Venous Pressure ◽  
Target Population ◽  
Diagnostic Value ◽  
Clinical Settings ◽  
Hepatic Decompensation ◽  
Noninvasive Methods ◽  
Noninvasive Diagnostics ◽  
Clinically Significant

AbstractNoninvasive diagnostics for portal hypertension include imaging and functional tests, as well as blood-based biomarkers, and capture different features of the portal hypertensive syndrome. Definitive conclusions regarding their clinical utility require assessment of their diagnostic value in specific clinical settings (i.e., diagnosing a particular hemodynamic condition within a well-defined target population). Several noninvasive methods are predictive of clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥ 10 mm Hg; the threshold for complications of portal hypertension); however, only a minority of them have been evaluated in compensated advanced chronic liver disease (i.e., the target population). Importantly, most methods correlate only weakly with HVPG at high values (i.e., in patients with CSPH). Nevertheless, selected methods show promise for diagnosing HVPG ≥ 16 mm Hg (the cut-off for increased risks of hepatic decompensation and mortality) and monitoring HVPG changes in response to nonselective beta-blockers or etiological treatments. Finally, we review established and potential future clinical applications of noninvasive methods.

Sign in / Sign up

Export Citation Format

Share Document